SENATE RESOLUTION 177--EXPRESSING SUPPORT FOR THE DESIGNATION OF APRIL 30, 2019, AS ``NATIONAL ADULT HEPATITIS B VACCINATION AWARENESS DAY''; Congressional Record Vol. 165, No. 70
(Senate - April 30, 2019)
Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Page S2524]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SENATE RESOLUTION 177--EXPRESSING SUPPORT FOR THE DESIGNATION OF APRIL
30, 2019, AS ``NATIONAL ADULT HEPATITIS B VACCINATION AWARENESS DAY''
Ms. HIRONO (for herself and Mr. King) submitted the following
resolution; which was referred to the Committee on Health, Education,
Labor, and Pensions:
S. Res. 177
Whereas as many as 2,200,000 individuals in the United
States are chronically infected with hepatitis B, and as many
as \2/3\ of those individuals are unaware of the infection;
Whereas hepatitis B is a viral infection of the liver that
is transmitted via infected blood and other bodily fluids,
including through--
(1) mother-to-child transmission; and
(2) injection drug use;
Whereas individuals with chronic diseases, such as
diabetes, HIV, hepatitis C, and chronic liver disease, and
individuals on hemodialysis, are at an increased risk for
hepatitis B co-infection;
Whereas there is no cure for hepatitis B, and individuals
with chronic hepatitis B require lifelong medical care;
Whereas chronic hepatitis B is a common cause of liver
cancer;
Whereas 1 in every 4 individuals with unmanaged chronic
hepatitis B will develop liver cancer, cirrhosis, or liver
failure, with liver cancer having a 5-year survival rate of
only 18 percent in the United States;
Whereas safe and highly effective vaccines to protect
against hepatitis B are available;
Whereas, in accordance with universal childhood hepatitis B
vaccination recommendations in the United States, infants and
children in the United States have routinely been vaccinated
against hepatitis B since the 1990s;
Whereas the hepatitis B vaccine, which is 95 percent
effective and was the first anticancer vaccine to be
developed, is projected to prevent 310,000,000 cases of
hepatitis B worldwide from 1990 to 2020;
Whereas only 25 percent of adults in the United States are
vaccinated against hepatitis B;
Whereas the number of reported acute hepatitis B cases
increased by 20 percent nationwide in 2015;
Whereas, as a result of the opioid epidemic, there have
been significant regional increases in acute hepatitis B
cases in the United States, including--
(1) a reported 729 percent increase from 2015 to 2017 in
Maine;
(2) a reported 114 percent increase from 2009 to 2013 in
Kentucky, West Virginia, and Tennessee;
(3) a reported 78 percent increase in 2017 in southeastern
Massachusetts; and
(4) a reported 62 percent increase from 2012 to 2016 in
North Carolina;
Whereas, according to the Centers for Disease Control and
Prevention, hepatitis B is 50 to 100 times more infectious
than HIV, and 5 to 10 times more infectious than hepatitis C;
and
Whereas there are significant opportunities, particularly
within the setting of the opioid epidemic, to prevent new
hepatitis B infections, and thereby reduce the incidence of
liver cancer and cirrhosis, through efforts to--
(1) increase adult hepatitis B vaccination; and
(2) maintain childhood hepatitis B vaccination: Now,
therefore, be it
Resolved, That the Senate--
(1) supports the designation of April 30, 2019, as
``National Adult Hepatitis B Vaccination Awareness Day'';
(2) recognizes the importance of providing support and
encouragement--
(A) for all individuals to be tested for hepatitis B;
(B) for individuals susceptible to infection to be
vaccinated against hepatitis B; and
(C) for individuals diagnosed with hepatitis B to be linked
to appropriate care; and
(3) in order to reduce the number of new hepatitis B
infections and hepatitis B-related deaths, encourages a
commitment to--
(A) increasing adult hepatitis B vaccination rates;
(B) maintaining childhood hepatitis B vaccination rates;
and
(C) promoting provider and community awareness of adult
hepatitis B vaccination.
____________________